A new study suggests a possible link between GLP-1 weight loss drugs like Ozempic and Mounjaro and vision problems, including sudden vision loss. Researchers are investigating whether these ...

Though you can hit speed bumps in your weight loss journey, Hone Health says there are minor tweaks you can make to get your ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

It’s a lot to expect perfection out of one player all the time and when the other side of the team can’t do much to help, this is the kind of sad, shocking ending you get to a season.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The drugmaker's shares were up nearly 5% at $882 in afternoon trading. The stock has more than doubled in value in the last two years, making it the most valuable healthcare company in the world, but ...

Investing.com - Eli Lilly’s (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...